nodes	percent_of_prediction	percent_of_DWPC	metapath
Haloperidol—CYP2D6—Fingolimod—multiple sclerosis	0.0496	0.1	CbGbCtD
Haloperidol—ABCB1—Methylprednisolone—multiple sclerosis	0.0339	0.0684	CbGbCtD
Haloperidol—CYP1A1—Dexamethasone—multiple sclerosis	0.0329	0.0662	CbGbCtD
Haloperidol—CYP3A4—Fingolimod—multiple sclerosis	0.0316	0.0636	CbGbCtD
Haloperidol—HTR1B—trigeminal nucleus—multiple sclerosis	0.0284	0.155	CbGeAlD
Haloperidol—HTR1D—trigeminal nucleus—multiple sclerosis	0.0275	0.15	CbGeAlD
Haloperidol—CYP3A7—Dexamethasone—multiple sclerosis	0.0263	0.053	CbGbCtD
Haloperidol—CYP3A7-CYP3A51P—Dexamethasone—multiple sclerosis	0.0263	0.053	CbGbCtD
Haloperidol—CYP2C19—Prednisone—multiple sclerosis	0.0255	0.0514	CbGbCtD
Haloperidol—ABCB1—Mitoxantrone—multiple sclerosis	0.0248	0.0499	CbGbCtD
Haloperidol—ABCB1—Betamethasone—multiple sclerosis	0.0221	0.0445	CbGbCtD
Haloperidol—ABCB1—Prednisolone—multiple sclerosis	0.0218	0.0439	CbGbCtD
Haloperidol—ABCB1—Prednisone—multiple sclerosis	0.0206	0.0414	CbGbCtD
Haloperidol—CYP3A4—Methylprednisolone—multiple sclerosis	0.0203	0.041	CbGbCtD
Haloperidol—CYP3A5—Dexamethasone—multiple sclerosis	0.0197	0.0398	CbGbCtD
Haloperidol—HTR1D—meninx—multiple sclerosis	0.0182	0.0993	CbGeAlD
Haloperidol—CYP2C19—Dexamethasone—multiple sclerosis	0.0159	0.0321	CbGbCtD
Haloperidol—CYP3A4—Triamcinolone—multiple sclerosis	0.0154	0.0311	CbGbCtD
Haloperidol—CYP3A4—Mitoxantrone—multiple sclerosis	0.0148	0.0299	CbGbCtD
Haloperidol—HTR2A—trigeminal nucleus—multiple sclerosis	0.0136	0.0743	CbGeAlD
Haloperidol—CYP2C9—Dexamethasone—multiple sclerosis	0.0132	0.0267	CbGbCtD
Haloperidol—CYP3A4—Betamethasone—multiple sclerosis	0.0132	0.0266	CbGbCtD
Haloperidol—CYP3A4—Prednisolone—multiple sclerosis	0.013	0.0263	CbGbCtD
Haloperidol—ABCB1—Dexamethasone—multiple sclerosis	0.0128	0.0259	CbGbCtD
Haloperidol—CYP3A4—Prednisone—multiple sclerosis	0.0123	0.0248	CbGbCtD
Haloperidol—CYP2D6—Dexamethasone—multiple sclerosis	0.0121	0.0244	CbGbCtD
Haloperidol—ABCB1—Methotrexate—multiple sclerosis	0.0103	0.0208	CbGbCtD
Haloperidol—CYP3A4—Dexamethasone—multiple sclerosis	0.00769	0.0155	CbGbCtD
Haloperidol—HTR1B—trigeminal nerve—multiple sclerosis	0.00745	0.0406	CbGeAlD
Haloperidol—HTR1D—trigeminal nerve—multiple sclerosis	0.00721	0.0393	CbGeAlD
Haloperidol—GRIN2B—nerve—multiple sclerosis	0.00559	0.0305	CbGeAlD
Haloperidol—HTR2A—trigeminal nerve—multiple sclerosis	0.00358	0.0195	CbGeAlD
Haloperidol—DRD1—nerve—multiple sclerosis	0.00336	0.0183	CbGeAlD
Haloperidol—HTR2A—pons—multiple sclerosis	0.00252	0.0137	CbGeAlD
Haloperidol—GRIN2B—brainstem—multiple sclerosis	0.0024	0.0131	CbGeAlD
Haloperidol—CBR1—Azacitidine—Cladribine—multiple sclerosis	0.00199	0.595	CbGdCrCtD
Haloperidol—DRD2—nerve—multiple sclerosis	0.00198	0.0108	CbGeAlD
Haloperidol—Loperamide—POMC—multiple sclerosis	0.00197	1	CrCbGaD
Haloperidol—HTR2A—pineal body—multiple sclerosis	0.0018	0.00981	CbGeAlD
Haloperidol—HTR2A—peripheral nervous system—multiple sclerosis	0.00168	0.00914	CbGeAlD
Haloperidol—GRIN2B—spinal cord—multiple sclerosis	0.00149	0.00814	CbGeAlD
Haloperidol—DRD1—brainstem—multiple sclerosis	0.00144	0.00785	CbGeAlD
Haloperidol—H1F0—retina—multiple sclerosis	0.00141	0.00767	CbGeAlD
Haloperidol—EBP—Azacitidine—Cladribine—multiple sclerosis	0.00135	0.405	CbGdCrCtD
Haloperidol—HTR2A—nerve—multiple sclerosis	0.00131	0.00713	CbGeAlD
Haloperidol—GRIN2B—nervous system—multiple sclerosis	0.00126	0.00686	CbGeAlD
Haloperidol—CBR1—medulla oblongata—multiple sclerosis	0.00124	0.00677	CbGeAlD
Haloperidol—GRIN2B—central nervous system—multiple sclerosis	0.00121	0.0066	CbGeAlD
Haloperidol—GRIN2B—cerebellum—multiple sclerosis	0.00118	0.00645	CbGeAlD
Haloperidol—HTR1B—brainstem—multiple sclerosis	0.00117	0.00636	CbGeAlD
Haloperidol—DRD4—brain—multiple sclerosis	0.00115	0.00625	CbGeAlD
Haloperidol—CBR1—midbrain—multiple sclerosis	0.00114	0.00618	CbGeAlD
Haloperidol—HTR1D—brainstem—multiple sclerosis	0.00113	0.00616	CbGeAlD
Haloperidol—CBR1—spinal cord—multiple sclerosis	0.00111	0.00603	CbGeAlD
Haloperidol—DRD3—nervous system—multiple sclerosis	0.00105	0.00574	CbGeAlD
Haloperidol—H1F0—medulla oblongata—multiple sclerosis	0.00102	0.00554	CbGeAlD
Haloperidol—DRD3—central nervous system—multiple sclerosis	0.00102	0.00553	CbGeAlD
Haloperidol—GRIN2B—brain—multiple sclerosis	0.000962	0.00524	CbGeAlD
Haloperidol—CBR1—nervous system—multiple sclerosis	0.000933	0.00508	CbGeAlD
Haloperidol—H1F0—midbrain—multiple sclerosis	0.00093	0.00507	CbGeAlD
Haloperidol—DRD1—midbrain—multiple sclerosis	0.000918	0.005	CbGeAlD
Haloperidol—H1F0—spinal cord—multiple sclerosis	0.000907	0.00494	CbGeAlD
Haloperidol—CBR1—central nervous system—multiple sclerosis	0.000898	0.0049	CbGeAlD
Haloperidol—CBR1—cerebellum—multiple sclerosis	0.000878	0.00478	CbGeAlD
Haloperidol—DRD2—brainstem—multiple sclerosis	0.000851	0.00464	CbGeAlD
Haloperidol—DRD2—retina—multiple sclerosis	0.000821	0.00448	CbGeAlD
Haloperidol—DRD3—brain—multiple sclerosis	0.000806	0.00439	CbGeAlD
Haloperidol—H1F0—nervous system—multiple sclerosis	0.000765	0.00417	CbGeAlD
Haloperidol—DRD1—nervous system—multiple sclerosis	0.000755	0.00411	CbGeAlD
Haloperidol—HTR1B—midbrain—multiple sclerosis	0.000744	0.00405	CbGeAlD
Haloperidol—H1F0—central nervous system—multiple sclerosis	0.000736	0.00401	CbGeAlD
Haloperidol—SIGMAR1—medulla oblongata—multiple sclerosis	0.000735	0.004	CbGeAlD
Haloperidol—DRD1—central nervous system—multiple sclerosis	0.000727	0.00396	CbGeAlD
Haloperidol—HTR1B—spinal cord—multiple sclerosis	0.000726	0.00396	CbGeAlD
Haloperidol—HTR1D—midbrain—multiple sclerosis	0.00072	0.00393	CbGeAlD
Haloperidol—H1F0—cerebellum—multiple sclerosis	0.000719	0.00392	CbGeAlD
Haloperidol—CBR1—brain—multiple sclerosis	0.000713	0.00389	CbGeAlD
Haloperidol—SIGMAR1—midbrain—multiple sclerosis	0.000672	0.00366	CbGeAlD
Haloperidol—SIGMAR1—spinal cord—multiple sclerosis	0.000655	0.00357	CbGeAlD
Haloperidol—HTR1B—nervous system—multiple sclerosis	0.000612	0.00333	CbGeAlD
Haloperidol—HTR1D—nervous system—multiple sclerosis	0.000592	0.00323	CbGeAlD
Haloperidol—HTR1B—central nervous system—multiple sclerosis	0.000589	0.00321	CbGeAlD
Haloperidol—KCNH2—medulla oblongata—multiple sclerosis	0.000585	0.00319	CbGeAlD
Haloperidol—H1F0—brain—multiple sclerosis	0.000584	0.00318	CbGeAlD
Haloperidol—DRD1—brain—multiple sclerosis	0.000577	0.00314	CbGeAlD
Haloperidol—HTR1D—central nervous system—multiple sclerosis	0.00057	0.00311	CbGeAlD
Haloperidol—HTR2A—brainstem—multiple sclerosis	0.000562	0.00306	CbGeAlD
Haloperidol—HTR2B—nervous system—multiple sclerosis	0.000551	0.003	CbGeAlD
Haloperidol—DRD2—midbrain—multiple sclerosis	0.000543	0.00296	CbGeAlD
Haloperidol—HTR2A—retina—multiple sclerosis	0.000542	0.00295	CbGeAlD
Haloperidol—KCNH2—midbrain—multiple sclerosis	0.000535	0.00291	CbGeAlD
Haloperidol—HTR2B—central nervous system—multiple sclerosis	0.00053	0.00289	CbGeAlD
Haloperidol—KCNH2—spinal cord—multiple sclerosis	0.000522	0.00284	CbGeAlD
Haloperidol—SIGMAR1—cerebellum—multiple sclerosis	0.00052	0.00283	CbGeAlD
Haloperidol—CYP2D6—brainstem—multiple sclerosis	0.000512	0.00279	CbGeAlD
Haloperidol—HTR1B—brain—multiple sclerosis	0.000468	0.00255	CbGeAlD
Haloperidol—HTR1D—brain—multiple sclerosis	0.000453	0.00247	CbGeAlD
Haloperidol—DRD2—nervous system—multiple sclerosis	0.000446	0.00243	CbGeAlD
Haloperidol—KCNH2—nervous system—multiple sclerosis	0.000439	0.00239	CbGeAlD
Haloperidol—DRD2—central nervous system—multiple sclerosis	0.000429	0.00234	CbGeAlD
Haloperidol—KCNH2—central nervous system—multiple sclerosis	0.000423	0.00231	CbGeAlD
Haloperidol—SIGMAR1—brain—multiple sclerosis	0.000422	0.0023	CbGeAlD
Haloperidol—HTR2B—brain—multiple sclerosis	0.000421	0.00229	CbGeAlD
Haloperidol—DRD2—cerebellum—multiple sclerosis	0.00042	0.00229	CbGeAlD
Haloperidol—KCNH2—cerebellum—multiple sclerosis	0.000414	0.00225	CbGeAlD
Haloperidol—HTR2A—medulla oblongata—multiple sclerosis	0.000392	0.00213	CbGeAlD
Haloperidol—CYP1A1—nervous system—multiple sclerosis	0.000371	0.00202	CbGeAlD
Haloperidol—HTR2A—midbrain—multiple sclerosis	0.000358	0.00195	CbGeAlD
Haloperidol—CYP1A1—central nervous system—multiple sclerosis	0.000357	0.00195	CbGeAlD
Haloperidol—ABCB1—retina—multiple sclerosis	0.000355	0.00193	CbGeAlD
Haloperidol—HRH1—nervous system—multiple sclerosis	0.000352	0.00192	CbGeAlD
Haloperidol—HTR2A—spinal cord—multiple sclerosis	0.000349	0.0019	CbGeAlD
Haloperidol—DRD2—brain—multiple sclerosis	0.000341	0.00186	CbGeAlD
Haloperidol—HRH1—central nervous system—multiple sclerosis	0.000339	0.00185	CbGeAlD
Haloperidol—KCNH2—brain—multiple sclerosis	0.000336	0.00183	CbGeAlD
Haloperidol—Headache—Cladribine—multiple sclerosis	0.000317	0.00175	CcSEcCtD
Haloperidol—Weight decreased—Prednisone—multiple sclerosis	0.000315	0.00174	CcSEcCtD
Haloperidol—Vision blurred—Prednisolone—multiple sclerosis	0.000315	0.00174	CcSEcCtD
Haloperidol—Hyperglycaemia—Prednisone—multiple sclerosis	0.000314	0.00174	CcSEcCtD
Haloperidol—Liver function test abnormal—Methotrexate—multiple sclerosis	0.000311	0.00172	CcSEcCtD
Haloperidol—Hypotension—Mitoxantrone—multiple sclerosis	0.000311	0.00172	CcSEcCtD
Haloperidol—Depression—Prednisone—multiple sclerosis	0.00031	0.00171	CcSEcCtD
Haloperidol—Visual impairment—Betamethasone—multiple sclerosis	0.000309	0.00171	CcSEcCtD
Haloperidol—Visual impairment—Dexamethasone—multiple sclerosis	0.000309	0.00171	CcSEcCtD
Haloperidol—Mental disorder—Methylprednisolone—multiple sclerosis	0.000309	0.0017	CcSEcCtD
Haloperidol—Malnutrition—Methylprednisolone—multiple sclerosis	0.000307	0.00169	CcSEcCtD
Haloperidol—Breast disorder—Methotrexate—multiple sclerosis	0.000305	0.00168	CcSEcCtD
Haloperidol—Hypersensitivity—Azathioprine—multiple sclerosis	0.000303	0.00167	CcSEcCtD
Haloperidol—Nausea—Cladribine—multiple sclerosis	0.0003	0.00166	CcSEcCtD
Haloperidol—Vertigo—Prednisolone—multiple sclerosis	0.0003	0.00166	CcSEcCtD
Haloperidol—Eye disorder—Betamethasone—multiple sclerosis	0.000299	0.00165	CcSEcCtD
Haloperidol—Eye disorder—Dexamethasone—multiple sclerosis	0.000299	0.00165	CcSEcCtD
Haloperidol—Dyspnoea—Mitoxantrone—multiple sclerosis	0.000296	0.00164	CcSEcCtD
Haloperidol—Somnolence—Mitoxantrone—multiple sclerosis	0.000296	0.00163	CcSEcCtD
Haloperidol—HTR2A—nervous system—multiple sclerosis	0.000294	0.0016	CbGeAlD
Haloperidol—Dyspepsia—Mitoxantrone—multiple sclerosis	0.000293	0.00162	CcSEcCtD
Haloperidol—Angiopathy—Betamethasone—multiple sclerosis	0.000291	0.00161	CcSEcCtD
Haloperidol—Angiopathy—Dexamethasone—multiple sclerosis	0.000291	0.00161	CcSEcCtD
Haloperidol—Convulsion—Prednisolone—multiple sclerosis	0.00029	0.0016	CcSEcCtD
Haloperidol—Decreased appetite—Mitoxantrone—multiple sclerosis	0.000289	0.0016	CcSEcCtD
Haloperidol—Hypertension—Prednisolone—multiple sclerosis	0.000289	0.00159	CcSEcCtD
Haloperidol—Constipation—Mitoxantrone—multiple sclerosis	0.000284	0.00157	CcSEcCtD
Haloperidol—CYP1A1—brain—multiple sclerosis	0.000284	0.00155	CbGeAlD
Haloperidol—HTR2A—central nervous system—multiple sclerosis	0.000283	0.00154	CbGeAlD
Haloperidol—Alopecia—Dexamethasone—multiple sclerosis	0.000283	0.00156	CcSEcCtD
Haloperidol—Alopecia—Betamethasone—multiple sclerosis	0.000283	0.00156	CcSEcCtD
Haloperidol—Diarrhoea—Azathioprine—multiple sclerosis	0.000281	0.00155	CcSEcCtD
Haloperidol—Hallucination—Prednisone—multiple sclerosis	0.000278	0.00153	CcSEcCtD
Haloperidol—HTR2A—cerebellum—multiple sclerosis	0.000277	0.00151	CbGeAlD
Haloperidol—Pancytopenia—Methotrexate—multiple sclerosis	0.000277	0.00153	CcSEcCtD
Haloperidol—Vertigo—Triamcinolone—multiple sclerosis	0.000276	0.00153	CcSEcCtD
Haloperidol—Vertigo—Methylprednisolone—multiple sclerosis	0.000276	0.00152	CcSEcCtD
Haloperidol—Connective tissue disorder—Prednisone—multiple sclerosis	0.000274	0.00151	CcSEcCtD
Haloperidol—Feeling abnormal—Mitoxantrone—multiple sclerosis	0.000274	0.00151	CcSEcCtD
Haloperidol—Anaphylactic shock—Prednisolone—multiple sclerosis	0.000273	0.00151	CcSEcCtD
Haloperidol—Oedema—Prednisolone—multiple sclerosis	0.000273	0.00151	CcSEcCtD
Haloperidol—Neutropenia—Methotrexate—multiple sclerosis	0.000272	0.0015	CcSEcCtD
Haloperidol—CYP3A4—nervous system—multiple sclerosis	0.000272	0.00148	CbGeAlD
Haloperidol—Dizziness—Azathioprine—multiple sclerosis	0.000272	0.0015	CcSEcCtD
Haloperidol—HRH1—brain—multiple sclerosis	0.000269	0.00147	CbGeAlD
Haloperidol—Erectile dysfunction—Methotrexate—multiple sclerosis	0.000268	0.00148	CcSEcCtD
Haloperidol—CYP2D6—nervous system—multiple sclerosis	0.000268	0.00146	CbGeAlD
Haloperidol—Convulsion—Triamcinolone—multiple sclerosis	0.000266	0.00147	CcSEcCtD
Haloperidol—Tachycardia—Prednisolone—multiple sclerosis	0.000266	0.00147	CcSEcCtD
Haloperidol—Photosensitivity reaction—Methotrexate—multiple sclerosis	0.000266	0.00147	CcSEcCtD
Haloperidol—Convulsion—Methylprednisolone—multiple sclerosis	0.000266	0.00147	CcSEcCtD
Haloperidol—Hypertension—Triamcinolone—multiple sclerosis	0.000265	0.00147	CcSEcCtD
Haloperidol—Hypertension—Methylprednisolone—multiple sclerosis	0.000265	0.00146	CcSEcCtD
Haloperidol—Urticaria—Mitoxantrone—multiple sclerosis	0.000264	0.00146	CcSEcCtD
Haloperidol—Hyperhidrosis—Prednisolone—multiple sclerosis	0.000264	0.00146	CcSEcCtD
Haloperidol—Body temperature increased—Mitoxantrone—multiple sclerosis	0.000263	0.00145	CcSEcCtD
Haloperidol—CYP3A4—central nervous system—multiple sclerosis	0.000262	0.00143	CbGeAlD
Haloperidol—Vomiting—Azathioprine—multiple sclerosis	0.000262	0.00144	CcSEcCtD
Haloperidol—Eye disorder—Prednisone—multiple sclerosis	0.000261	0.00144	CcSEcCtD
Haloperidol—Anxiety—Methylprednisolone—multiple sclerosis	0.00026	0.00144	CcSEcCtD
Haloperidol—Drowsiness—Methotrexate—multiple sclerosis	0.00026	0.00143	CcSEcCtD
Haloperidol—Rash—Azathioprine—multiple sclerosis	0.000259	0.00143	CcSEcCtD
Haloperidol—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—multiple sclerosis	0.000259	0.00143	CcSEcCtD
Haloperidol—Dermatitis—Azathioprine—multiple sclerosis	0.000259	0.00143	CcSEcCtD
Haloperidol—Depression—Methotrexate—multiple sclerosis	0.000259	0.00143	CcSEcCtD
Haloperidol—CYP2D6—central nervous system—multiple sclerosis	0.000258	0.00141	CbGeAlD
Haloperidol—Headache—Azathioprine—multiple sclerosis	0.000258	0.00142	CcSEcCtD
Haloperidol—ABCB1—medulla oblongata—multiple sclerosis	0.000257	0.0014	CbGeAlD
Haloperidol—Dry mouth—Triamcinolone—multiple sclerosis	0.000256	0.00141	CcSEcCtD
Haloperidol—Angiopathy—Prednisone—multiple sclerosis	0.000253	0.0014	CcSEcCtD
Haloperidol—Confusional state—Methylprednisolone—multiple sclerosis	0.000252	0.00139	CcSEcCtD
Haloperidol—CYP2D6—cerebellum—multiple sclerosis	0.000252	0.00137	CbGeAlD
Haloperidol—Immune system disorder—Prednisone—multiple sclerosis	0.000252	0.00139	CcSEcCtD
Haloperidol—Anaphylactic shock—Triamcinolone—multiple sclerosis	0.000251	0.00139	CcSEcCtD
Haloperidol—Oedema—Triamcinolone—multiple sclerosis	0.000251	0.00139	CcSEcCtD
Haloperidol—Vertigo—Betamethasone—multiple sclerosis	0.000251	0.00138	CcSEcCtD
Haloperidol—Vertigo—Dexamethasone—multiple sclerosis	0.000251	0.00138	CcSEcCtD
Haloperidol—Anaphylactic shock—Methylprednisolone—multiple sclerosis	0.00025	0.00138	CcSEcCtD
Haloperidol—Insomnia—Prednisolone—multiple sclerosis	0.000247	0.00136	CcSEcCtD
Haloperidol—Alopecia—Prednisone—multiple sclerosis	0.000247	0.00136	CcSEcCtD
Haloperidol—Hepatobiliary disease—Methotrexate—multiple sclerosis	0.000246	0.00136	CcSEcCtD
Haloperidol—Nervous system disorder—Methylprednisolone—multiple sclerosis	0.000245	0.00136	CcSEcCtD
Haloperidol—Hypersensitivity—Mitoxantrone—multiple sclerosis	0.000245	0.00135	CcSEcCtD
Haloperidol—Tachycardia—Triamcinolone—multiple sclerosis	0.000245	0.00135	CcSEcCtD
Haloperidol—Mental disorder—Prednisone—multiple sclerosis	0.000244	0.00135	CcSEcCtD
Haloperidol—Nausea—Azathioprine—multiple sclerosis	0.000244	0.00135	CcSEcCtD
Haloperidol—Tachycardia—Methylprednisolone—multiple sclerosis	0.000244	0.00135	CcSEcCtD
Haloperidol—Skin disorder—Methylprednisolone—multiple sclerosis	0.000243	0.00134	CcSEcCtD
Haloperidol—Malnutrition—Prednisone—multiple sclerosis	0.000243	0.00134	CcSEcCtD
Haloperidol—Hyperhidrosis—Triamcinolone—multiple sclerosis	0.000243	0.00134	CcSEcCtD
Haloperidol—Agranulocytosis—Methotrexate—multiple sclerosis	0.000242	0.00134	CcSEcCtD
Haloperidol—Hyperhidrosis—Methylprednisolone—multiple sclerosis	0.000242	0.00134	CcSEcCtD
Haloperidol—Convulsion—Betamethasone—multiple sclerosis	0.000242	0.00133	CcSEcCtD
Haloperidol—Convulsion—Dexamethasone—multiple sclerosis	0.000242	0.00133	CcSEcCtD
Haloperidol—Hypertension—Dexamethasone—multiple sclerosis	0.000241	0.00133	CcSEcCtD
Haloperidol—Hypertension—Betamethasone—multiple sclerosis	0.000241	0.00133	CcSEcCtD
Haloperidol—Anxiety—Betamethasone—multiple sclerosis	0.000237	0.00131	CcSEcCtD
Haloperidol—Anxiety—Dexamethasone—multiple sclerosis	0.000237	0.00131	CcSEcCtD
Haloperidol—ABCB1—midbrain—multiple sclerosis	0.000235	0.00128	CbGeAlD
Haloperidol—Hypotension—Methylprednisolone—multiple sclerosis	0.000234	0.00129	CcSEcCtD
Haloperidol—Hepatitis—Methotrexate—multiple sclerosis	0.000233	0.00129	CcSEcCtD
Haloperidol—Urinary tract disorder—Methotrexate—multiple sclerosis	0.00023	0.00127	CcSEcCtD
Haloperidol—Vision blurred—Prednisone—multiple sclerosis	0.000229	0.00126	CcSEcCtD
Haloperidol—ABCB1—spinal cord—multiple sclerosis	0.000229	0.00125	CbGeAlD
Haloperidol—Urethral disorder—Methotrexate—multiple sclerosis	0.000229	0.00126	CcSEcCtD
Haloperidol—Anaphylactic shock—Betamethasone—multiple sclerosis	0.000228	0.00126	CcSEcCtD
Haloperidol—Anaphylactic shock—Dexamethasone—multiple sclerosis	0.000228	0.00126	CcSEcCtD
Haloperidol—Oedema—Betamethasone—multiple sclerosis	0.000228	0.00126	CcSEcCtD
Haloperidol—Oedema—Dexamethasone—multiple sclerosis	0.000228	0.00126	CcSEcCtD
Haloperidol—Diarrhoea—Mitoxantrone—multiple sclerosis	0.000228	0.00126	CcSEcCtD
Haloperidol—Insomnia—Triamcinolone—multiple sclerosis	0.000227	0.00125	CcSEcCtD
Haloperidol—Insomnia—Methylprednisolone—multiple sclerosis	0.000226	0.00125	CcSEcCtD
Haloperidol—HTR2A—brain—multiple sclerosis	0.000225	0.00123	CbGeAlD
Haloperidol—Feeling abnormal—Prednisolone—multiple sclerosis	0.000225	0.00124	CcSEcCtD
Haloperidol—Visual impairment—Methotrexate—multiple sclerosis	0.000225	0.00124	CcSEcCtD
Haloperidol—Anaemia—Prednisone—multiple sclerosis	0.000224	0.00124	CcSEcCtD
Haloperidol—Dyspnoea—Triamcinolone—multiple sclerosis	0.000224	0.00124	CcSEcCtD
Haloperidol—Nervous system disorder—Dexamethasone—multiple sclerosis	0.000223	0.00123	CcSEcCtD
Haloperidol—Nervous system disorder—Betamethasone—multiple sclerosis	0.000223	0.00123	CcSEcCtD
Haloperidol—Agitation—Prednisone—multiple sclerosis	0.000223	0.00123	CcSEcCtD
Haloperidol—Thrombocytopenia—Dexamethasone—multiple sclerosis	0.000223	0.00123	CcSEcCtD
Haloperidol—Thrombocytopenia—Betamethasone—multiple sclerosis	0.000223	0.00123	CcSEcCtD
Haloperidol—Tachycardia—Betamethasone—multiple sclerosis	0.000222	0.00123	CcSEcCtD
Haloperidol—Tachycardia—Dexamethasone—multiple sclerosis	0.000222	0.00123	CcSEcCtD
Haloperidol—Dyspepsia—Triamcinolone—multiple sclerosis	0.000221	0.00122	CcSEcCtD
Haloperidol—Dyspepsia—Methylprednisolone—multiple sclerosis	0.00022	0.00122	CcSEcCtD
Haloperidol—Hyperhidrosis—Dexamethasone—multiple sclerosis	0.00022	0.00122	CcSEcCtD
Haloperidol—Hyperhidrosis—Betamethasone—multiple sclerosis	0.00022	0.00122	CcSEcCtD
Haloperidol—Vertigo—Prednisone—multiple sclerosis	0.000218	0.00121	CcSEcCtD
Haloperidol—Eye disorder—Methotrexate—multiple sclerosis	0.000218	0.0012	CcSEcCtD
Haloperidol—Anorexia—Betamethasone—multiple sclerosis	0.000217	0.0012	CcSEcCtD
Haloperidol—Anorexia—Dexamethasone—multiple sclerosis	0.000217	0.0012	CcSEcCtD
Haloperidol—Urticaria—Prednisolone—multiple sclerosis	0.000217	0.0012	CcSEcCtD
Haloperidol—Cardiac disorder—Methotrexate—multiple sclerosis	0.000216	0.0012	CcSEcCtD
Haloperidol—Hypotension—Dexamethasone—multiple sclerosis	0.000213	0.00117	CcSEcCtD
Haloperidol—Hypotension—Betamethasone—multiple sclerosis	0.000213	0.00117	CcSEcCtD
Haloperidol—Angiopathy—Methotrexate—multiple sclerosis	0.000212	0.00117	CcSEcCtD
Haloperidol—Vomiting—Mitoxantrone—multiple sclerosis	0.000211	0.00117	CcSEcCtD
Haloperidol—Immune system disorder—Methotrexate—multiple sclerosis	0.000211	0.00116	CcSEcCtD
Haloperidol—Convulsion—Prednisone—multiple sclerosis	0.00021	0.00116	CcSEcCtD
Haloperidol—Mediastinal disorder—Methotrexate—multiple sclerosis	0.00021	0.00116	CcSEcCtD
Haloperidol—Hypertension—Prednisone—multiple sclerosis	0.00021	0.00116	CcSEcCtD
Haloperidol—Rash—Mitoxantrone—multiple sclerosis	0.00021	0.00116	CcSEcCtD
Haloperidol—Dermatitis—Mitoxantrone—multiple sclerosis	0.000209	0.00116	CcSEcCtD
Haloperidol—Headache—Mitoxantrone—multiple sclerosis	0.000208	0.00115	CcSEcCtD
Haloperidol—Feeling abnormal—Triamcinolone—multiple sclerosis	0.000207	0.00114	CcSEcCtD
Haloperidol—Feeling abnormal—Methylprednisolone—multiple sclerosis	0.000206	0.00114	CcSEcCtD
Haloperidol—Anxiety—Prednisone—multiple sclerosis	0.000206	0.00114	CcSEcCtD
Haloperidol—Alopecia—Methotrexate—multiple sclerosis	0.000206	0.00114	CcSEcCtD
Haloperidol—Insomnia—Betamethasone—multiple sclerosis	0.000206	0.00114	CcSEcCtD
Haloperidol—Insomnia—Dexamethasone—multiple sclerosis	0.000206	0.00114	CcSEcCtD
Haloperidol—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	0.000205	0.00113	CcSEcCtD
Haloperidol—CYP2D6—brain—multiple sclerosis	0.000205	0.00112	CbGeAlD
Haloperidol—Mental disorder—Methotrexate—multiple sclerosis	0.000204	0.00113	CcSEcCtD
Haloperidol—Malnutrition—Methotrexate—multiple sclerosis	0.000203	0.00112	CcSEcCtD
Haloperidol—Hypersensitivity—Prednisolone—multiple sclerosis	0.000201	0.00111	CcSEcCtD
Haloperidol—Dyspepsia—Dexamethasone—multiple sclerosis	0.0002	0.00111	CcSEcCtD
Haloperidol—Dyspepsia—Betamethasone—multiple sclerosis	0.0002	0.00111	CcSEcCtD
Haloperidol—Urticaria—Triamcinolone—multiple sclerosis	0.000199	0.0011	CcSEcCtD
Haloperidol—Urticaria—Methylprednisolone—multiple sclerosis	0.000199	0.0011	CcSEcCtD
Haloperidol—Body temperature increased—Triamcinolone—multiple sclerosis	0.000198	0.0011	CcSEcCtD
Haloperidol—Anaphylactic shock—Prednisone—multiple sclerosis	0.000198	0.00109	CcSEcCtD
Haloperidol—Oedema—Prednisone—multiple sclerosis	0.000198	0.00109	CcSEcCtD
Haloperidol—Decreased appetite—Betamethasone—multiple sclerosis	0.000198	0.00109	CcSEcCtD
Haloperidol—Decreased appetite—Dexamethasone—multiple sclerosis	0.000198	0.00109	CcSEcCtD
Haloperidol—Nausea—Mitoxantrone—multiple sclerosis	0.000198	0.00109	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Betamethasone—multiple sclerosis	0.000197	0.00109	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	0.000197	0.00109	CcSEcCtD
Haloperidol—Nervous system disorder—Prednisone—multiple sclerosis	0.000194	0.00107	CcSEcCtD
Haloperidol—Tachycardia—Prednisone—multiple sclerosis	0.000193	0.00107	CcSEcCtD
Haloperidol—ABCB1—nervous system—multiple sclerosis	0.000193	0.00105	CbGeAlD
Haloperidol—Skin disorder—Prednisone—multiple sclerosis	0.000193	0.00106	CcSEcCtD
Haloperidol—Hyperhidrosis—Prednisone—multiple sclerosis	0.000192	0.00106	CcSEcCtD
Haloperidol—Vision blurred—Methotrexate—multiple sclerosis	0.000191	0.00106	CcSEcCtD
Haloperidol—Anorexia—Prednisone—multiple sclerosis	0.000189	0.00104	CcSEcCtD
Haloperidol—Anaemia—Methotrexate—multiple sclerosis	0.000188	0.00104	CcSEcCtD
Haloperidol—Feeling abnormal—Dexamethasone—multiple sclerosis	0.000188	0.00104	CcSEcCtD
Haloperidol—Feeling abnormal—Betamethasone—multiple sclerosis	0.000188	0.00104	CcSEcCtD
Haloperidol—ABCB1—central nervous system—multiple sclerosis	0.000186	0.00101	CbGeAlD
Haloperidol—Hypersensitivity—Triamcinolone—multiple sclerosis	0.000185	0.00102	CcSEcCtD
Haloperidol—Hypersensitivity—Methylprednisolone—multiple sclerosis	0.000184	0.00102	CcSEcCtD
Haloperidol—Vertigo—Methotrexate—multiple sclerosis	0.000182	0.00101	CcSEcCtD
Haloperidol—Leukopenia—Methotrexate—multiple sclerosis	0.000182	0.001	CcSEcCtD
Haloperidol—ABCB1—cerebellum—multiple sclerosis	0.000181	0.000989	CbGeAlD
Haloperidol—Urticaria—Betamethasone—multiple sclerosis	0.000181	0.000999	CcSEcCtD
Haloperidol—Urticaria—Dexamethasone—multiple sclerosis	0.000181	0.000999	CcSEcCtD
Haloperidol—Dizziness—Prednisolone—multiple sclerosis	0.00018	0.000996	CcSEcCtD
Haloperidol—Body temperature increased—Dexamethasone—multiple sclerosis	0.00018	0.000994	CcSEcCtD
Haloperidol—Body temperature increased—Betamethasone—multiple sclerosis	0.00018	0.000994	CcSEcCtD
Haloperidol—Insomnia—Prednisone—multiple sclerosis	0.000179	0.00099	CcSEcCtD
Haloperidol—Pruritus—Triamcinolone—multiple sclerosis	0.000177	0.00098	CcSEcCtD
Haloperidol—Pruritus—Methylprednisolone—multiple sclerosis	0.000177	0.000978	CcSEcCtD
Haloperidol—Convulsion—Methotrexate—multiple sclerosis	0.000176	0.000971	CcSEcCtD
Haloperidol—Dyspepsia—Prednisone—multiple sclerosis	0.000174	0.000964	CcSEcCtD
Haloperidol—Decreased appetite—Prednisone—multiple sclerosis	0.000172	0.000952	CcSEcCtD
Haloperidol—Rash—Prednisolone—multiple sclerosis	0.000172	0.00095	CcSEcCtD
Haloperidol—Dermatitis—Prednisolone—multiple sclerosis	0.000172	0.000949	CcSEcCtD
Haloperidol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	0.000172	0.000948	CcSEcCtD
Haloperidol—Diarrhoea—Methylprednisolone—multiple sclerosis	0.000171	0.000946	CcSEcCtD
Haloperidol—Headache—Prednisolone—multiple sclerosis	0.000171	0.000944	CcSEcCtD
Haloperidol—Constipation—Prednisone—multiple sclerosis	0.00017	0.000936	CcSEcCtD
Haloperidol—Confusional state—Methotrexate—multiple sclerosis	0.000167	0.000923	CcSEcCtD
Haloperidol—Dizziness—Triamcinolone—multiple sclerosis	0.000166	0.000916	CcSEcCtD
Haloperidol—Anaphylactic shock—Methotrexate—multiple sclerosis	0.000166	0.000915	CcSEcCtD
Haloperidol—Dizziness—Methylprednisolone—multiple sclerosis	0.000166	0.000914	CcSEcCtD
Haloperidol—Feeling abnormal—Prednisone—multiple sclerosis	0.000163	0.000902	CcSEcCtD
Haloperidol—Nervous system disorder—Methotrexate—multiple sclerosis	0.000162	0.000897	CcSEcCtD
Haloperidol—Thrombocytopenia—Methotrexate—multiple sclerosis	0.000162	0.000896	CcSEcCtD
Haloperidol—Nausea—Prednisolone—multiple sclerosis	0.000162	0.000895	CcSEcCtD
Haloperidol—Pruritus—Betamethasone—multiple sclerosis	0.000161	0.00089	CcSEcCtD
Haloperidol—Pruritus—Dexamethasone—multiple sclerosis	0.000161	0.00089	CcSEcCtD
Haloperidol—Skin disorder—Methotrexate—multiple sclerosis	0.000161	0.000889	CcSEcCtD
Haloperidol—Hyperhidrosis—Methotrexate—multiple sclerosis	0.00016	0.000885	CcSEcCtD
Haloperidol—Vomiting—Triamcinolone—multiple sclerosis	0.000159	0.000881	CcSEcCtD
Haloperidol—Vomiting—Methylprednisolone—multiple sclerosis	0.000159	0.000879	CcSEcCtD
Haloperidol—Rash—Triamcinolone—multiple sclerosis	0.000158	0.000874	CcSEcCtD
Haloperidol—Dermatitis—Triamcinolone—multiple sclerosis	0.000158	0.000873	CcSEcCtD
Haloperidol—Anorexia—Methotrexate—multiple sclerosis	0.000158	0.000872	CcSEcCtD
Haloperidol—Rash—Methylprednisolone—multiple sclerosis	0.000158	0.000872	CcSEcCtD
Haloperidol—Dermatitis—Methylprednisolone—multiple sclerosis	0.000158	0.000871	CcSEcCtD
Haloperidol—Urticaria—Prednisone—multiple sclerosis	0.000157	0.00087	CcSEcCtD
Haloperidol—Headache—Triamcinolone—multiple sclerosis	0.000157	0.000868	CcSEcCtD
Haloperidol—Headache—Methylprednisolone—multiple sclerosis	0.000157	0.000866	CcSEcCtD
Haloperidol—Body temperature increased—Prednisone—multiple sclerosis	0.000157	0.000866	CcSEcCtD
Haloperidol—Diarrhoea—Betamethasone—multiple sclerosis	0.000156	0.00086	CcSEcCtD
Haloperidol—Diarrhoea—Dexamethasone—multiple sclerosis	0.000156	0.00086	CcSEcCtD
Haloperidol—Hypotension—Methotrexate—multiple sclerosis	0.000155	0.000855	CcSEcCtD
Haloperidol—Dizziness—Dexamethasone—multiple sclerosis	0.000151	0.000831	CcSEcCtD
Haloperidol—Dizziness—Betamethasone—multiple sclerosis	0.000151	0.000831	CcSEcCtD
Haloperidol—Insomnia—Methotrexate—multiple sclerosis	0.00015	0.000828	CcSEcCtD
Haloperidol—Nausea—Triamcinolone—multiple sclerosis	0.000149	0.000823	CcSEcCtD
Haloperidol—Nausea—Methylprednisolone—multiple sclerosis	0.000149	0.000821	CcSEcCtD
Haloperidol—Dyspnoea—Methotrexate—multiple sclerosis	0.000148	0.000816	CcSEcCtD
Haloperidol—ABCB1—brain—multiple sclerosis	0.000147	0.000803	CbGeAlD
Haloperidol—Somnolence—Methotrexate—multiple sclerosis	0.000147	0.000814	CcSEcCtD
Haloperidol—Hypersensitivity—Prednisone—multiple sclerosis	0.000146	0.000807	CcSEcCtD
Haloperidol—Dyspepsia—Methotrexate—multiple sclerosis	0.000146	0.000806	CcSEcCtD
Haloperidol—Vomiting—Dexamethasone—multiple sclerosis	0.000145	0.000799	CcSEcCtD
Haloperidol—Vomiting—Betamethasone—multiple sclerosis	0.000145	0.000799	CcSEcCtD
Haloperidol—Decreased appetite—Methotrexate—multiple sclerosis	0.000144	0.000795	CcSEcCtD
Haloperidol—Rash—Betamethasone—multiple sclerosis	0.000144	0.000793	CcSEcCtD
Haloperidol—Rash—Dexamethasone—multiple sclerosis	0.000144	0.000793	CcSEcCtD
Haloperidol—Dermatitis—Betamethasone—multiple sclerosis	0.000143	0.000792	CcSEcCtD
Haloperidol—Dermatitis—Dexamethasone—multiple sclerosis	0.000143	0.000792	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Methotrexate—multiple sclerosis	0.000143	0.00079	CcSEcCtD
Haloperidol—Headache—Betamethasone—multiple sclerosis	0.000143	0.000788	CcSEcCtD
Haloperidol—Headache—Dexamethasone—multiple sclerosis	0.000143	0.000788	CcSEcCtD
Haloperidol—Pruritus—Prednisone—multiple sclerosis	0.00014	0.000775	CcSEcCtD
Haloperidol—Feeling abnormal—Methotrexate—multiple sclerosis	0.000137	0.000754	CcSEcCtD
Haloperidol—Diarrhoea—Prednisone—multiple sclerosis	0.000136	0.000749	CcSEcCtD
Haloperidol—Nausea—Dexamethasone—multiple sclerosis	0.000135	0.000747	CcSEcCtD
Haloperidol—Nausea—Betamethasone—multiple sclerosis	0.000135	0.000747	CcSEcCtD
Haloperidol—Urticaria—Methotrexate—multiple sclerosis	0.000132	0.000727	CcSEcCtD
Haloperidol—Dizziness—Prednisone—multiple sclerosis	0.000131	0.000724	CcSEcCtD
Haloperidol—Body temperature increased—Methotrexate—multiple sclerosis	0.000131	0.000723	CcSEcCtD
Haloperidol—Vomiting—Prednisone—multiple sclerosis	0.000126	0.000696	CcSEcCtD
Haloperidol—Rash—Prednisone—multiple sclerosis	0.000125	0.00069	CcSEcCtD
Haloperidol—Dermatitis—Prednisone—multiple sclerosis	0.000125	0.00069	CcSEcCtD
Haloperidol—Headache—Prednisone—multiple sclerosis	0.000124	0.000686	CcSEcCtD
Haloperidol—Hypersensitivity—Methotrexate—multiple sclerosis	0.000122	0.000674	CcSEcCtD
Haloperidol—Nausea—Prednisone—multiple sclerosis	0.000118	0.00065	CcSEcCtD
Haloperidol—Pruritus—Methotrexate—multiple sclerosis	0.000117	0.000647	CcSEcCtD
Haloperidol—Diarrhoea—Methotrexate—multiple sclerosis	0.000113	0.000626	CcSEcCtD
Haloperidol—Dizziness—Methotrexate—multiple sclerosis	0.00011	0.000605	CcSEcCtD
Haloperidol—Vomiting—Methotrexate—multiple sclerosis	0.000105	0.000582	CcSEcCtD
Haloperidol—Rash—Methotrexate—multiple sclerosis	0.000104	0.000577	CcSEcCtD
Haloperidol—Dermatitis—Methotrexate—multiple sclerosis	0.000104	0.000576	CcSEcCtD
Haloperidol—Headache—Methotrexate—multiple sclerosis	0.000104	0.000573	CcSEcCtD
Haloperidol—Nausea—Methotrexate—multiple sclerosis	9.84e-05	0.000544	CcSEcCtD
Haloperidol—HRH1—Signaling Pathways—CD28—multiple sclerosis	1.65e-05	0.000123	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	1.65e-05	0.000123	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—SPP1—multiple sclerosis	1.63e-05	0.000122	CbGpPWpGaD
Haloperidol—DRD3—Signaling by GPCR—TYK2—multiple sclerosis	1.63e-05	0.000122	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—CCR5—multiple sclerosis	1.62e-05	0.000121	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—CCR2—multiple sclerosis	1.62e-05	0.000121	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—CCR2—multiple sclerosis	1.62e-05	0.000121	CbGpPWpGaD
Haloperidol—HTR2B—GPCR downstream signaling—IL2—multiple sclerosis	1.61e-05	0.00012	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—SPP1—multiple sclerosis	1.61e-05	0.00012	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—IL2RA—multiple sclerosis	1.6e-05	0.000119	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—CCR5—multiple sclerosis	1.59e-05	0.000119	CbGpPWpGaD
Haloperidol—HTR1D—Signaling by GPCR—IL2—multiple sclerosis	1.59e-05	0.000119	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—CD86—multiple sclerosis	1.59e-05	0.000119	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—BCHE—multiple sclerosis	1.58e-05	0.000118	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	1.58e-05	0.000118	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—IL2RA—multiple sclerosis	1.57e-05	0.000117	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—CD86—multiple sclerosis	1.57e-05	0.000117	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—CCR5—multiple sclerosis	1.56e-05	0.000117	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—CCL5—multiple sclerosis	1.56e-05	0.000117	CbGpPWpGaD
Haloperidol—UGT1A9—Metabolism—APOE—multiple sclerosis	1.56e-05	0.000117	CbGpPWpGaD
Haloperidol—HTR1B—Signaling by GPCR—IL2—multiple sclerosis	1.56e-05	0.000116	CbGpPWpGaD
Haloperidol—DRD2—GPCR downstream signaling—POMC—multiple sclerosis	1.55e-05	0.000116	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—CCL5—multiple sclerosis	1.54e-05	0.000115	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—IL2RA—multiple sclerosis	1.54e-05	0.000115	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—GPC5—multiple sclerosis	1.54e-05	0.000115	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—SPP1—multiple sclerosis	1.54e-05	0.000115	CbGpPWpGaD
Haloperidol—DRD4—Signaling by GPCR—IL2—multiple sclerosis	1.53e-05	0.000114	CbGpPWpGaD
Haloperidol—HTR2A—GPCR downstream signaling—POMC—multiple sclerosis	1.52e-05	0.000114	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—CNR1—multiple sclerosis	1.52e-05	0.000114	CbGpPWpGaD
Haloperidol—HRH1—GPCR downstream signaling—POMC—multiple sclerosis	1.52e-05	0.000114	CbGpPWpGaD
Haloperidol—DRD1—GPCR downstream signaling—IL2—multiple sclerosis	1.52e-05	0.000113	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	1.5e-05	0.000112	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—CNR1—multiple sclerosis	1.5e-05	0.000112	CbGpPWpGaD
Haloperidol—DRD3—GPCR downstream signaling—IL2—multiple sclerosis	1.5e-05	0.000112	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—CNR1—multiple sclerosis	1.5e-05	0.000112	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—CCR5—multiple sclerosis	1.49e-05	0.000111	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—BCHE—multiple sclerosis	1.49e-05	0.000111	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—APOE—multiple sclerosis	1.48e-05	0.00011	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—IL2RA—multiple sclerosis	1.47e-05	0.00011	CbGpPWpGaD
Haloperidol—HTR2B—Signaling by GPCR—IL2—multiple sclerosis	1.46e-05	0.000109	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—SPP1—multiple sclerosis	1.45e-05	0.000108	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—APOE—multiple sclerosis	1.45e-05	0.000108	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—SPP1—multiple sclerosis	1.43e-05	0.000107	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—APOE—multiple sclerosis	1.42e-05	0.000106	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	1.42e-05	0.000106	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—CCR5—multiple sclerosis	1.41e-05	0.000105	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—POMC—multiple sclerosis	1.41e-05	0.000105	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—CCR5—multiple sclerosis	1.39e-05	0.000104	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—IL2RA—multiple sclerosis	1.39e-05	0.000104	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—POMC—multiple sclerosis	1.38e-05	0.000103	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—POMC—multiple sclerosis	1.38e-05	0.000103	CbGpPWpGaD
Haloperidol—DRD1—Signaling by GPCR—IL2—multiple sclerosis	1.38e-05	0.000103	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—CCL2—multiple sclerosis	1.38e-05	0.000103	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—CXCL10—multiple sclerosis	1.37e-05	0.000102	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—IL2RA—multiple sclerosis	1.37e-05	0.000102	CbGpPWpGaD
Haloperidol—DRD3—Signaling by GPCR—IL2—multiple sclerosis	1.36e-05	0.000101	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—APOE—multiple sclerosis	1.36e-05	0.000101	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—CCL2—multiple sclerosis	1.35e-05	0.000101	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—CCL2—multiple sclerosis	1.35e-05	0.000101	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—CXCL10—multiple sclerosis	1.35e-05	0.000101	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—CXCL10—multiple sclerosis	1.35e-05	0.0001	CbGpPWpGaD
Haloperidol—UGT1A9—Metabolism—POMC—multiple sclerosis	1.34e-05	0.0001	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—CD80—multiple sclerosis	1.34e-05	9.97e-05	CbGpPWpGaD
Haloperidol—CYP3A7—Metabolism—APOE—multiple sclerosis	1.31e-05	9.8e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—CD80—multiple sclerosis	1.31e-05	9.76e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	1.29e-05	9.63e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	1.29e-05	9.63e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—CD80—multiple sclerosis	1.29e-05	9.61e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	1.28e-05	9.58e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—APOE—multiple sclerosis	1.28e-05	9.56e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—RRM1—multiple sclerosis	1.28e-05	9.53e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—POMC—multiple sclerosis	1.27e-05	9.47e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—APOE—multiple sclerosis	1.26e-05	9.44e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—TYK2—multiple sclerosis	1.25e-05	9.33e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—POMC—multiple sclerosis	1.24e-05	9.28e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—CCL2—multiple sclerosis	1.24e-05	9.27e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—TYK2—multiple sclerosis	1.23e-05	9.18e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—CD80—multiple sclerosis	1.23e-05	9.17e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—TYK2—multiple sclerosis	1.23e-05	9.16e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—POMC—multiple sclerosis	1.22e-05	9.13e-05	CbGpPWpGaD
Haloperidol—UGT1A9—Metabolism—ALB—multiple sclerosis	1.22e-05	9.13e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—BCHE—multiple sclerosis	1.22e-05	9.1e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—CCL2—multiple sclerosis	1.22e-05	9.08e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling by GPCR—MAPK1—multiple sclerosis	1.21e-05	9.07e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—CD86—multiple sclerosis	1.2e-05	8.95e-05	CbGpPWpGaD
Haloperidol—ABCB1—Transmembrane transport of small molecules—ALB—multiple sclerosis	1.2e-05	8.94e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—CCL2—multiple sclerosis	1.2e-05	8.93e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—BCHE—multiple sclerosis	1.19e-05	8.89e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling by GPCR—MAPK1—multiple sclerosis	1.19e-05	8.88e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—CCL5—multiple sclerosis	1.18e-05	8.81e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—CD86—multiple sclerosis	1.18e-05	8.81e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—CD86—multiple sclerosis	1.18e-05	8.79e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	1.18e-05	8.78e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling by GPCR—MAPK1—multiple sclerosis	1.17e-05	8.74e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—POMC—multiple sclerosis	1.17e-05	8.71e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—CCL5—multiple sclerosis	1.16e-05	8.67e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—CCL5—multiple sclerosis	1.16e-05	8.65e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—CD80—multiple sclerosis	1.16e-05	8.65e-05	CbGpPWpGaD
Haloperidol—DRD2—GPCR downstream signaling—IL2—multiple sclerosis	1.15e-05	8.55e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—CD80—multiple sclerosis	1.14e-05	8.53e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—CCL2—multiple sclerosis	1.14e-05	8.53e-05	CbGpPWpGaD
Haloperidol—CYP3A7—Metabolism—POMC—multiple sclerosis	1.13e-05	8.42e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—TYK2—multiple sclerosis	1.13e-05	8.42e-05	CbGpPWpGaD
Haloperidol—HTR2A—GPCR downstream signaling—IL2—multiple sclerosis	1.13e-05	8.41e-05	CbGpPWpGaD
Haloperidol—HRH1—GPCR downstream signaling—IL2—multiple sclerosis	1.12e-05	8.39e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—BCHE—multiple sclerosis	1.12e-05	8.37e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling by GPCR—MAPK1—multiple sclerosis	1.12e-05	8.34e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—BCHE—multiple sclerosis	1.11e-05	8.3e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—TYK2—multiple sclerosis	1.1e-05	8.24e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	1.1e-05	8.23e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—POMC—multiple sclerosis	1.1e-05	8.22e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—SPP1—multiple sclerosis	1.09e-05	8.16e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—TYK2—multiple sclerosis	1.09e-05	8.11e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—POMC—multiple sclerosis	1.09e-05	8.11e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—CCL2—multiple sclerosis	1.08e-05	8.04e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—SPP1—multiple sclerosis	1.08e-05	8.03e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—SPP1—multiple sclerosis	1.07e-05	8.01e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—CCR5—multiple sclerosis	1.06e-05	7.94e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—CCL2—multiple sclerosis	1.06e-05	7.93e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling by GPCR—MAPK1—multiple sclerosis	1.05e-05	7.87e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—IL2RA—multiple sclerosis	1.05e-05	7.82e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—CCR5—multiple sclerosis	1.05e-05	7.81e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—CCR5—multiple sclerosis	1.04e-05	7.79e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—IL2—multiple sclerosis	1.04e-05	7.76e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling by GPCR—MAPK1—multiple sclerosis	1.04e-05	7.76e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—TYK2—multiple sclerosis	1.04e-05	7.74e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—IL2RA—multiple sclerosis	1.03e-05	7.7e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—IL2RA—multiple sclerosis	1.03e-05	7.68e-05	CbGpPWpGaD
Haloperidol—CYP3A7—Metabolism—ALB—multiple sclerosis	1.03e-05	7.68e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—IL2—multiple sclerosis	1.02e-05	7.64e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—IL2—multiple sclerosis	1.02e-05	7.62e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	1.01e-05	7.51e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—TYK2—multiple sclerosis	9.78e-06	7.3e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—APOE—multiple sclerosis	9.68e-06	7.22e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—TYK2—multiple sclerosis	9.65e-06	7.2e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—APOE—multiple sclerosis	9.52e-06	7.11e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—BCHE—multiple sclerosis	9.5e-06	7.09e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—APOE—multiple sclerosis	9.5e-06	7.09e-05	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—APOE—multiple sclerosis	9.49e-06	7.08e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—IL2—multiple sclerosis	9.38e-06	7e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling by GPCR—IL6—multiple sclerosis	9.34e-06	6.97e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—IL2—multiple sclerosis	9.19e-06	6.86e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling by GPCR—IL6—multiple sclerosis	9.14e-06	6.82e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—IL2—multiple sclerosis	9.04e-06	6.75e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling by GPCR—IL6—multiple sclerosis	9e-06	6.71e-05	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—APOE—multiple sclerosis	8.97e-06	6.69e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—MMP9—multiple sclerosis	8.88e-06	6.63e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—CD80—multiple sclerosis	8.75e-06	6.53e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—MMP9—multiple sclerosis	8.7e-06	6.49e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—IL2—multiple sclerosis	8.63e-06	6.44e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—CD80—multiple sclerosis	8.61e-06	6.42e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—CD80—multiple sclerosis	8.59e-06	6.41e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling by GPCR—IL6—multiple sclerosis	8.59e-06	6.41e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—MMP9—multiple sclerosis	8.56e-06	6.39e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—POMC—multiple sclerosis	8.31e-06	6.2e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—POMC—multiple sclerosis	8.18e-06	6.1e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—MMP9—multiple sclerosis	8.17e-06	6.1e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—POMC—multiple sclerosis	8.16e-06	6.09e-05	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—POMC—multiple sclerosis	8.15e-06	6.09e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—IL2—multiple sclerosis	8.14e-06	6.07e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—CCL2—multiple sclerosis	8.13e-06	6.07e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling by GPCR—IL6—multiple sclerosis	8.1e-06	6.04e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—IL2—multiple sclerosis	8.03e-06	5.99e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—CCL2—multiple sclerosis	8e-06	5.97e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling by GPCR—IL6—multiple sclerosis	7.99e-06	5.96e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—CCL2—multiple sclerosis	7.98e-06	5.96e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—MAPK1—multiple sclerosis	7.96e-06	5.94e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—STAT3—multiple sclerosis	7.9e-06	5.89e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—MAPK1—multiple sclerosis	7.83e-06	5.84e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—MAPK1—multiple sclerosis	7.81e-06	5.83e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—STAT3—multiple sclerosis	7.73e-06	5.77e-05	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—POMC—multiple sclerosis	7.7e-06	5.75e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—MMP9—multiple sclerosis	7.7e-06	5.75e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—STAT3—multiple sclerosis	7.61e-06	5.68e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—MMP9—multiple sclerosis	7.6e-06	5.67e-05	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—ALB—multiple sclerosis	7.43e-06	5.55e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—TYK2—multiple sclerosis	7.38e-06	5.51e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—APOE—multiple sclerosis	7.34e-06	5.48e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—MYC—multiple sclerosis	7.34e-06	5.48e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—BCHE—multiple sclerosis	7.34e-06	5.48e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—TGFB1—multiple sclerosis	7.32e-06	5.46e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—TYK2—multiple sclerosis	7.27e-06	5.42e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—STAT3—multiple sclerosis	7.26e-06	5.42e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—TYK2—multiple sclerosis	7.25e-06	5.41e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—MYC—multiple sclerosis	7.18e-06	5.36e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—MAPK1—multiple sclerosis	7.18e-06	5.36e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—TGFB1—multiple sclerosis	7.17e-06	5.35e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—APOE—multiple sclerosis	7.16e-06	5.35e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—MYC—multiple sclerosis	7.07e-06	5.28e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—TGFB1—multiple sclerosis	7.05e-06	5.26e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—MAPK1—multiple sclerosis	7.03e-06	5.25e-05	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—ALB—multiple sclerosis	7.02e-06	5.24e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—MAPK1—multiple sclerosis	6.92e-06	5.16e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—STAT3—multiple sclerosis	6.85e-06	5.11e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—STAT3—multiple sclerosis	6.76e-06	5.04e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—APOE—multiple sclerosis	6.75e-06	5.04e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—MYC—multiple sclerosis	6.75e-06	5.04e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—TGFB1—multiple sclerosis	6.73e-06	5.02e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—APOE—multiple sclerosis	6.69e-06	4.99e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—MAPK1—multiple sclerosis	6.6e-06	4.93e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—MYC—multiple sclerosis	6.36e-06	4.75e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—TGFB1—multiple sclerosis	6.35e-06	4.74e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—POMC—multiple sclerosis	6.3e-06	4.71e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—MYC—multiple sclerosis	6.28e-06	4.69e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—TGFB1—multiple sclerosis	6.26e-06	4.68e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—MAPK1—multiple sclerosis	6.23e-06	4.65e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—POMC—multiple sclerosis	6.15e-06	4.59e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—IL2—multiple sclerosis	6.14e-06	4.59e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—MAPK1—multiple sclerosis	6.14e-06	4.58e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—IL6—multiple sclerosis	6.11e-06	4.56e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—IL2—multiple sclerosis	6.05e-06	4.51e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—IL2—multiple sclerosis	6.03e-06	4.5e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—IL6—multiple sclerosis	6.02e-06	4.49e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—IL6—multiple sclerosis	6e-06	4.48e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—MMP9—multiple sclerosis	5.82e-06	4.34e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—POMC—multiple sclerosis	5.8e-06	4.33e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—POMC—multiple sclerosis	5.75e-06	4.29e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—ALB—multiple sclerosis	5.75e-06	4.29e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—MMP9—multiple sclerosis	5.72e-06	4.27e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—APOE—multiple sclerosis	5.72e-06	4.27e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—MMP9—multiple sclerosis	5.71e-06	4.26e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—ALB—multiple sclerosis	5.61e-06	4.19e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—IL6—multiple sclerosis	5.52e-06	4.12e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—IL6—multiple sclerosis	5.4e-06	4.03e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—IL6—multiple sclerosis	5.31e-06	3.97e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—ALB—multiple sclerosis	5.29e-06	3.95e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—ALB—multiple sclerosis	5.24e-06	3.91e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—STAT3—multiple sclerosis	5.17e-06	3.86e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—STAT3—multiple sclerosis	5.09e-06	3.8e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—STAT3—multiple sclerosis	5.08e-06	3.79e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—IL6—multiple sclerosis	5.07e-06	3.79e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—POMC—multiple sclerosis	4.91e-06	3.67e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—MYC—multiple sclerosis	4.8e-06	3.59e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—TGFB1—multiple sclerosis	4.79e-06	3.58e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—IL6—multiple sclerosis	4.78e-06	3.57e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—MYC—multiple sclerosis	4.73e-06	3.53e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—IL6—multiple sclerosis	4.72e-06	3.52e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—MYC—multiple sclerosis	4.72e-06	3.52e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—TGFB1—multiple sclerosis	4.72e-06	3.52e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—TGFB1—multiple sclerosis	4.71e-06	3.51e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—MAPK1—multiple sclerosis	4.7e-06	3.51e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—MAPK1—multiple sclerosis	4.63e-06	3.45e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—MAPK1—multiple sclerosis	4.62e-06	3.44e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—ALB—multiple sclerosis	4.48e-06	3.34e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—APOE—multiple sclerosis	4.41e-06	3.29e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—POMC—multiple sclerosis	3.79e-06	2.83e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—IL6—multiple sclerosis	3.61e-06	2.7e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—IL6—multiple sclerosis	3.55e-06	2.65e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—IL6—multiple sclerosis	3.55e-06	2.65e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—ALB—multiple sclerosis	3.46e-06	2.58e-05	CbGpPWpGaD
